Shares of Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA – Get Rating) rose 1.6% on Thursday . The stock traded as high as $1.24 and last traded at $1.24. Approximately 20,126 shares were traded during mid-day trading, a decline of 99% from the average daily volume of 2,304,068 shares. The stock had previously closed at $1.22.
Comera Life Sciences Stock Up 1.6 %
The company has a 50 day moving average of $1.40 and a two-hundred day moving average of $2.06.
Get
Comera Life Sciences alerts:
Comera Life Sciences (NASDAQ:CMRA – Get Rating) last issued its quarterly earnings results on Thursday, November 10th. The company reported ($0.20) earnings per share for the quarter. The company had revenue of $0.24 million during the quarter.
Insider Transactions at Comera Life Sciences
In related news, major shareholder Charles Cherington bought 15,266 shares of the business's stock in a transaction dated Monday, October 17th. The shares were purchased at an average cost of $1.66 per share, with a total value of $25,341.56. Following the completion of the purchase, the insider now owns 634,930 shares in the company, valued at approximately $1,053,983.80. The purchase was disclosed in a filing with the SEC, which is accessible through
the SEC website. Over the last three months, insiders have purchased 32,063 shares of company stock valued at $51,920.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of CMRA. Jane Street Group LLC bought a new position in Comera Life Sciences in the second quarter valued at about $115,000. Lake Street Advisors Group LLC lifted its holdings in Comera Life Sciences by 216.5% in the third quarter. Lake Street Advisors Group LLC now owns 316,469 shares of the company's stock valued at $510,000 after acquiring an additional 216,469 shares during the period. Virtu Financial LLC bought a new position in Comera Life Sciences in the third quarter valued at about $25,000. Arena Investors LP bought a new position in Comera Life Sciences in the third quarter valued at about $137,000. Finally, Bluefin Capital Management LLC bought a new position in Comera Life Sciences in the second quarter valued at about $73,000. 2.94% of the stock is owned by institutional investors.
Comera Life Sciences Company Profile
(Get Rating)
Comera Life Sciences Holdings, Inc, a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore. Its SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions.
Recommended Stories
- Get a free copy of the StockNews.com research report on Comera Life Sciences (CMRA)
- Should You Warm up to Generac Stock for the Winter?
- Is Kintara Therapeutics A Hidden Gem?
- 3 High-Yield Dividend Stocks to Hold for the Long Haul
- Cal-Maine Posts Record Quarter, Remain CALM Income Investors
- Tesla Stock: What the Bulls and the Bears Are Getting Wrong
Receive News & Ratings for Comera Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Comera Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
